Imperial College London

DrDraganaMilojkovic

Faculty of MedicineDepartment of Immunology and Inflammation

Professor of Practice (Chronic Myeloid Malignancies)
 
 
 
//

Contact

 

+44 (0)20 3313 5038d.milojkovic

 
 
//

Location

 

Cancer CentreHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

5 results found

Maynard S, Ros-Soto J, Chaidos A, Innes A, Paleja K, Mirvis E, Buti N, Sharp H, Palanicawandar R, Milojkovic Det al., 2021, The role of ibrutinib in COVID-19 hyperinflammation: a case report, International Journal of Infectious Diseases, Vol: 105, Pages: 274-276, ISSN: 1201-9712

Continuing ibrutinib in patients with COVID-19 may be advantageous given its immunomodulatory properties and withdrawal of ibrutinib therapy may be detrimental. Further evidence is required to explore the potential therapeutic impact of BTKis and other immunomodulatory agents on the clinical course of COVID-19 as is currently being carried out in a number of clinical trials.

Journal article

Claudiani S, Apperley JF, Deplano S, Khorashad J, Foroni L, Palanicawandar R, Perry R, Milojkovic Det al., 2016, Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia, American Journal of Hematology, Vol: 91, Pages: E480-E481, ISSN: 1096-8652

Journal article

Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic Det al., 2014, Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 164, Pages: 608-610, ISSN: 0007-1048

Journal article

Milojkovic D, Apperley J, 2008, State-of-the-art in the treatment of chronic myeloid leukaemia, CURRENT OPINION IN ONCOLOGY, Vol: 20, Pages: 112-121, ISSN: 1040-8746

Journal article

De Melo VA, Milojkovic D, Khorashad JS, Marin D, Goldman JM, Apperley JF, Reid AGet al., 2007, Philadelphia-negative clonal haematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukaemia, Blood, Vol: 110, Pages: 3086-3087

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00518121&limit=30&person=true